Nectar Lifesciences Ltd Proposes Buyback of Equity Shares to Reward Shareholders and Strengthen Financial Health

Nectar Lifesciences Limited recently approved a proposal for the buyback of its equity shares, as endorsed by the Board of Directors in their meeting held on July 23, 2025. The buyback is part of a comprehensive strategy to reward shareholders and improve financial flexibility amid ongoing restructuring initiatives.

The buyback may be executed via special dividends and/or equity share repurchases, allowing the company to manage capital efficiently while returning value directly to shareholders. This move complements Nectar's earlier initiatives, including the repayment of a substantial secured debt and sale of core business assets, designed to streamline operations and strengthen the balance sheet.

The company emphasized that the proceeds from these efforts will enable targeted investments in new projects and strategic priorities, fostering long-term growth. The formal shareholder approval and detailed modalities will be communicated in due course.

Key Highlights:

Board approved proposal for equity share buyback to reward shareholders.

Buyback to be conducted in conjunction with special dividends or a mix of both.

Aligns with company’s financial restructuring and debt repayment milestones.

Enhances capital efficiency and supports strategic investment opportunities.

Part of broader efforts to strengthen balance sheet and operational focus.

Formal approvals and buyback details to follow regulatory compliance.

Sources: NSE India official filings, EquityBulls, company disclosures​